UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 45

Sortiert nach

Unmet challenges in systemic therapy for early stage breast cancer

Breast (Edinburgh), 2022-03, Vol.62 (Suppl 1), p.S67-S69

Burstein, Harold J.

2022

Link zum Volltext

Verfügbarkeit prüfen

Aromatase inhibitor-associated arthralgia syndrome

Breast (Edinburgh), 2007-06, Vol.16 (3), p.223-234

Burstein, Harold J

2007

Link zum Volltext

Verfügbarkeit prüfen

Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review

Progress in cardiovascular diseases, 2010-09, Vol.53 (2), p.94-104

2010

Link zum Volltext

Verfügbarkeit prüfen

Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer

Hematology/oncology clinics of North America, 2023-02, Vol.37 (1), p.xiii-xvi

Burstein, Harold J.

2023

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit

Breast (Edinburgh), 2019-11, Vol.48 Suppl 1, p.S89-S91

Burstein, Harold J

2019

Link zum Volltext

Verfügbarkeit prüfen

Breast Cancer Treatment in the Era of Individualized Care

Hematology/oncology clinics of North America, 2013-08, Vol.27 (4), p.xiii-xv

Burstein, Harold J., MD, PhD

2013

Link zum Volltext

Verfügbarkeit prüfen

Novel Agents and Future Directions for Refractory Breast Cancer

Seminars in oncology, 2011-06, Vol.38, p.S17-S24

Burstein, Harold J

2011

Link zum Volltext

Verfügbarkeit prüfen

Chemotherapy for Metastatic Breast Cancer

Hematology/oncology clinics of North America, 2007-04, Vol.21 (2), p.257-272

2007

Link zum Volltext

Verfügbarkeit prüfen

Introduction: Current and Future Approaches to Chemotherapy in Patients With Resistant Breast Cancer

Seminars in oncology, 2011-06, Vol.38, p.S1-S2

2011

Link zum Volltext

Verfügbarkeit prüfen

Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer

International journal of radiation oncology, biology, physics, 2022-05, Vol.113 (1), p.117-124

2022

Link zum Volltext

Verfügbarkeit prüfen

The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer

Cancer treatment reviews, 2024-07, Vol.128, p.102761-102761, Article 102761

2024

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant Hormonal Therapy for Early-Stage Breast Cancer

Surgical oncology clinics of North America, 2010-07, Vol.19 (3), p.639-647

2010

Link zum Volltext

Verfügbarkeit prüfen

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era

Breast (Edinburgh), 2013-08, Vol.22 (4), p.525-531

2013

Link zum Volltext

Verfügbarkeit prüfen

Postmenopausal breast cancer: a best endocrine strategy?

The Lancet (British edition), 2015-10, Vol.386 (10001), p.1317-1319

2015

Link zum Volltext

Verfügbarkeit prüfen

Patients with triple negative breast cancer: Is there an optimal adjuvant treatment?

Breast (Edinburgh), 2013-08, Vol.22, p.S147-S148

Burstein, Harold J

2013

Link zum Volltext

Verfügbarkeit prüfen

Biological Basis of Breast Cancer: An Introduction

Seminars in oncology, 2007-04, Vol.34 (2 Suppl 3), p.S1-S3

2007

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant endocrine therapy for postmenopausal women: Type and duration

Breast (Edinburgh), 2015-11, Vol.24, p.S126-S128

2015

Link zum Volltext

Verfügbarkeit prüfen

Breast Cancer

Hematology/oncology clinics of North America, 2023-02, Vol.37 (1), p.i

Burstein, Harold J.

2023

Link zum Volltext

Verfügbarkeit prüfen

Patients with anti-HER2 responsive disease: definition and adjuvant therapies

Breast (Edinburgh), 2011-10, Vol.20, p.S132-S134

Burstein, Harold J

2011

Link zum Volltext

Verfügbarkeit prüfen

Breast Cancer

Hematology/oncology clinics of North America, 2023-02, Vol.37 (1), p.i-i

Burstein, Harold J.

2023

Link zum Volltext

Verfügbarkeit prüfen

Cognitive side-effects of adjuvant treatments

Breast (Edinburgh), 2007, Vol.16, p.166-168

Burstein, Harold J

2007

Link zum Volltext

Verfügbarkeit prüfen

Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study

Clinical breast cancer, 2013-08, Vol.13 (4), p.254-263

2013

Link zum Volltext

Verfügbarkeit prüfen

Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit1

Breast (Edinburgh), 2019-11, Vol.48, p.S89-S91

Burstein, Harold J.

2019

Link zum Volltext

Verfügbarkeit prüfen

Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer

Clinical breast cancer, 2015-02, Vol.15 (1), p.24-30

2015

Link zum Volltext

Verfügbarkeit prüfen

Gemcitabine-induced radiation recall

International journal of radiation oncology, biology, physics, 2002-06, Vol.53 (2), p.394-400

2002

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 45

Suche als RSS-Feed

Aktive Filter

ThemaChemotherapy

KollektionElsevier ScienceDirect Journals Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(45)
Mit Volltextzugriff
(36)

Publikationsform

Artikel
(45)

Sprache

Englisch
(45)
Japanisch
(2)

Erscheinungsjahr

n.n

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Unmet challenges in systemic therapy for early stage breast cancer

Aromatase inhibitor-associated arthralgia syndrome

Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review

Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer

Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit

Breast Cancer Treatment in the Era of Individualized Care

Novel Agents and Future Directions for Refractory Breast Cancer

Chemotherapy for Metastatic Breast Cancer

Introduction: Current and Future Approaches to Chemotherapy in Patients With Resistant Breast Cancer

Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer

The evolving landscape of metastatic HER2-positive, hormone receptor-positive Breast Cancer

Adjuvant Hormonal Therapy for Early-Stage Breast Cancer

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era

Postmenopausal breast cancer: a best endocrine strategy?

Patients with triple negative breast cancer: Is there an optimal adjuvant treatment?

Biological Basis of Breast Cancer: An Introduction

Adjuvant endocrine therapy for postmenopausal women: Type and duration

Breast Cancer

Patients with anti-HER2 responsive disease: definition and adjuvant therapies

Breast Cancer

Cognitive side-effects of adjuvant treatments

Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study

Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit1

Long-Term Follow-Up After Preoperative Trastuzumab and Chemotherapy for HER2-Overexpressing Breast Cancer

Gemcitabine-induced radiation recall

Aktive Filter

Suchergebnisse filtern